Viewing Study NCT05068206


Ignite Creation Date: 2025-12-26 @ 1:19 PM
Ignite Modification Date: 2026-03-09 @ 4:14 AM
Study NCT ID: NCT05068206
Status: UNKNOWN
Last Update Posted: 2021-10-20
First Post: 2021-09-24
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module